DNMT3A mutations emerged as potential biomarkers for enhanced immunotherapy benefit in non-small cell lung cancer.

Nuvation Bio Inc. (NYSE:NUVB) is one of the 10 best healthcare penny stocks to buy according to analysts. JMP Securities ...

A new research paper was published in Volume 16 of Oncotarget on June 17, 2025, titled "Molecular landscape of HER2-mutated ...

A new cancer drug candidate developed by Lawrence Livermore National Laboratory, BridgeBio Oncology Therapeutics and ...

A study led by Dana-Farber Cancer Institute researchers found that combining chemotherapy and immunotherapy before surgery ...

Targeted therapies and immunotherapy can provide benefits when added to chemotherapy or may eliminate the need for ...

Elevated NLR may no longer predict poor survival outcomes in patients with small cell lung cancer (SCLC) receiving ...

Lung cancer remains the leading cause of cancer mortality worldwide. Immunotherapy has recently emerged as a promising therapeutic strategy both for ...

A new cancer drug candidate has demonstrated the ability to block tumor growth without triggering a common and debilitating ...

The company said the therapy is the first allogenic therapy developed with its Tmod technology to be tested in humans.

The firm will evaluate VS-7375 as both monotherapy and in combination with Eli Lilly's EGFR inhibitor Erbitux in the study.

Understanding how tumors manipulate their microenvironment is key to improving cancer immunotherapy. A recent study has revealed that PKM2, a metabolic enzyme released from necrotic tumor cells, acts ...